August 2021 — Vol 141 No 8

MCC pathogenetic pathways and immune infiltrate patterns.

In this issue of the JID, Lahman and colleagues discuss the weak to absent correlation between total mutation burden (TMB) and responsiveness of Merkel cell carcinoma (MCC) tumors to immune checkpoint inhibitor therapy. Quality trumps quantity (see pages 1897-1905 for details).